Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells

• Published in: Cancer chemotherapy and pharmacology Vol. 37; no. 5; p. 486
• Main Authors: Tang, H Y, Weber, K L, Lawrence, T S, Merchant, A K, Maybaum, J
• Format: Journal Article
• Language: English
• Published: Germany 1996
• Subjects: Antimetabolites, Antineoplastic - pharmacology; Base Composition; Cell Cycle - drug effects; Cell Separation; Cell Survival - drug effects; Colonic Neoplasms - pathology; DNA Damage; DNA, Neoplasm - chemistry; DNA, Neoplasm - drug effects; Electrophoresis, Agar Gel; Floxuridine - pharmacology; HT29 Cells - drug effects; Humans; S Phase - drug effects
• ISSN: 0344-5704
• DOI: 10.1007/s002800050416

The relationship between cell cycle progression and induction of DNA double-strand breaks and cytotoxicity by exposure to fluorodeoxyuridine (FdUrd) was studied in HT29 human colon cancer cells. Fractionation of drug-treated populations by centrifugal elutriation yielded subpopulations having widely divergent abilities to progress through S phase in the presence of the drug. One of these subpopulations, which appeared to undergo coordinated growth arrest, was resistant to FdUrd cytotoxicity and DNA damage. In contrast, the subpopulation which was able to progress furthest through S phase in the presence of FdUrd underwent unbalanced growth arrest (i.e., increase in size and mass out of proportion to DNA synthesis), and displayed both DNA double-strand break formation (assayed by pulsed field gel electrophoresis) and loss of clonogenicity. When cells were elutriated prior to drug treatment, producing fractions enriched in cells at various cell cycle stages, no significant differences in sensitivity to FdUrd-induced cytotoxicity were detected among elutriation fractions. These findings support the model that, in HT29 cells, progression into and through S phase during drug treatment is an important determinant of FdUrd-induced DNA damage and cytotoxicity, but that the cell cycle position at the start of drug exposure is not a critical factor for these effects.